Moderna-Merck cancer vaccine success raises questions over its use against other cancers
The personalised mRNA vaccine reduced the risk of melanoma recurrence or death by 42% when combined with Keytruda in a Phase 3 trial. However, researchers are still investigating why it works and whether the approach can be extended to other cancer types.
Written by: Fatima hasanUpdated:








